Grant: Project Grant - PA: Breast Cancer Research
McGill University
$100,000.00
Characterization of human TFE3 isoforms as drivers in breast cancer
FY 2022-23
Summary
Breast cancer is the most common cancer diagnosed in women worldwide. There are different types of breast cancer and each one shows a different prognostic outcome. Each year only ~ 20 % of patients get diagnosed with Triple-Negative Breast Cancer (TNBC); however, it is responsible for a large proportion of breast cancer deaths because it is very aggressive and is more likely to spread to other parts of the body at diagnosis (metastasis). This makes essential to identify key drivers of metastasis that can be therapeutically targeted. TFE3 is a transcription factor with a critical role in the regulation of key cellular processes that are activated in many cancers, such as cell survival, development of new blood vessels, metabolic adaptation, drug resistance, and response to stress. Transcription factors are proteins that turn specific genes "on" or "off" by binding to nearby DNA. In humans, we detected two forms of TFE3, isoforms 1 and 2. Interestingly, we found that the levels of TFE3 isoform 1 are higher in TNBC cells compared to cells from less aggressive breast cancer types. We have identified the mechanism of how TFE3 isoform 1 levels are controlled. In this proposal, we want to further understand how these two TFE3 isoforms contribute to cancer development and metastasis. We will identify the specific genes turned "on" or "off" by each TFE3 isoform. We expect TFE3 isoform 2 to be important for tumor progression and high levels of TFE3 isoform 1 to be a key factor in breast cancer metastasis. Our studies will provide insights into the development of targeted therapies for the treatment of aggressive breast cancer.
Department
Program
Project Grant - PA: Breast Cancer Research
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
472347
Name
Pause Arnim P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Characterization of human TFE3 isoforms as drivers in breast cancer
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Breast Cancer; Metastasis; Tfe3; Tnbc; Transcription; Tumor Progression
Abstract
Breast cancer is the most common cancer diagnosed in women worldwide. There are different types of breast cancer and each one shows a different prognostic outcome. Each year only ~ 20 % of patients get diagnosed with Triple-Negative Breast Cancer (TNBC); however, it is responsible for a large proportion of breast cancer deaths because it is very aggressive and is more likely to spread to other parts of the body at diagnosis (metastasis). This makes essential to identify key drivers of metastasis that can be therapeutically targeted. TFE3 is a transcription factor with a critical role in the regulation of key cellular processes that are activated in many cancers, such as cell survival, development of new blood vessels, metabolic adaptation, drug resistance, and response to stress. Transcription factors are proteins that turn specific genes "on" or "off" by binding to nearby DNA. In humans, we detected two forms of TFE3, isoforms 1 and 2. Interestingly, we found that the levels of TFE3 isoform 1 are higher in TNBC cells compared to cells from less aggressive breast cancer types. We have identified the mechanism of how TFE3 isoform 1 levels are controlled. In this proposal, we want to further understand how these two TFE3 isoforms contribute to cancer development and metastasis. We will identify the specific genes turned "on" or "off" by each TFE3 isoform. We expect TFE3 isoform 2 to be important for tumor progression and high levels of TFE3 isoform 1 to be a key factor in breast cancer metastasis. Our studies will provide insights into the development of targeted therapies for the treatment of aggressive breast cancer.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pause, Arnim P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~